IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. &...
August 08 2016 - 2:43PM
Business Wire
Khang & Khang LLP (the “Firm”) announces that a class action
lawsuit was filed against Keryx Biopharmaceuticals Inc. (“Keryx” or
the “Company”) (Nasdaq: KERX). Investors who purchased or otherwise
acquired shares between February 25, 2016 and August 1, 2016
inclusive (the “Class Period”), are encouraged to contact the Firm
prior to the October 3, 2016 lead plaintiff motion
deadline.
If you purchased shares of Keryx during the Class Period, please
contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von
Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
According to the complaint, the Company made false and
misleading statements and/or failed to disclose that Keryx was
experiencing production-related difficulties in converting API to
finished drug product; that the issue was resulting in decreased
production yields of finished drug product; that the Company
exhausted its reserve of finished drug product; and as a result of
the above, Keryx’s statements about its business, operations and
prospects were false and misleading and/or lacked a reasonable
basis at all relevant times.
If you wish to learn more about this lawsuit, or if
you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160808006053/en/
Khang & Khang LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024